Climb Bio (CLYM) Cash from Operations (2020 - 2026)
Climb Bio's (CLYM) quarterly Cash from Operations came in at 14379000.0 in Q1 2026, up 6.84% YoY from 13459002.12 in Q1 2025, and up 8.03% on a QoQ basis from 15635000.0 in Q4 2025.
Powered by 
Analysis
Climb Bio (CLYM) Cash from Operations (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Cash from Operations data on file, last reported at 14379000.0 in Q1 2026.
- Quarterly Cash from Operations rose 6.84% year-over-year to 14379000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53301000.0 (down 82.68% YoY) and the FY2025 annual result came in at 54356000.0, down 249.29% from the prior year.
- Cash from Operations climbed to 14379000.0 in Q1 2026, from 15635000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3490000.0 in Q3 2023 to a low of 15635000.0 in Q4 2025.
- A 5-year average of 8368529.41 and a median of 8449000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 183.59% — and 2025, when it tumbled 1571.36%.
- Tracing CLYM's Cash from Operations over 5 years: stood at 8449000.0 in 2022, then jumped by 88.79% to 947000.0 in 2023, then sank by 483.0% to 5521000.0 in 2024, then tumbled by 183.19% to 15635000.0 in 2025, then increased by 8.03% to 14379000.0 in 2026.
- The last three Cash from Operations figures came in at 14379000.0 (Q1 2026), 15635000.0 (Q4 2025), and 12139000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - | -10.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.55 Mn |
| Mar 31, 2026 | -14.38 Mn |
| Dec 31, 2025 | -15.64 Mn |
| Sep 30, 2025 | -12.14 Mn |
| Jun 30, 2025 | -11.15 Mn |
| Mar 31, 2025 | -15.43 Mn |
| Dec 31, 2024 | -5.52 Mn |
| Sep 30, 2024 | -7.56 Mn |
| Jun 30, 2024 | -667,000.00 |
| Mar 31, 2024 | -1.82 Mn |
| Dec 31, 2023 | -947,000.00 |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | -7.97 Mn |
| Mar 31, 2023 | -15.18 Mn |
| Dec 31, 2022 | -8.45 Mn |
| Sep 30, 2022 | -4.18 Mn |
| Jun 30, 2022 | -13.97 Mn |
| Mar 31, 2022 | -10.78 Mn |
| Dec 31, 2021 | -7.88 Mn |
| Sep 30, 2021 | -12.97 Mn |